Jay M Sosenko1. 1. Division of Endocrinology, University of Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: There are an increasing number of markers that are used to predict the occurrence of type 1 diabetes (T1D), and to study the progression of pathologic changes prior to diagnosis. This review discusses some of those markers, particularly markers for which data are available that pertain to the progression to T1D. RECENT FINDINGS: A study of birth cohorts showed that young children who develop multiple autoantibodies are at a particularly high risk for developing T1D, and that there appears to be a typical sequence for autoantibody development. The measurement of autoantibodies by electrochemiluminescence can increase the prediction accuracy for T1D. A new marker of changes in glucose over 6 months (PS6 M) has potential utility as an endpoint in short-term prevention trials. Markers which combine C-peptide and glucose, such as the Diabetes Prevention Trial-Type 1 Risk Score and the Index60, can increase the accuracy of prediction, and can potentially be utilized as prediagnostic endpoints. β-cell death measurements could have substantial utility in future T1D research. SUMMARY: Markers are highly useful for studying the prediction of and progression to T1D. Moreover, markers can possibly be utilized to diagnose T1D at an earlier stage of disease.
PURPOSE OF REVIEW: There are an increasing number of markers that are used to predict the occurrence of type 1 diabetes (T1D), and to study the progression of pathologic changes prior to diagnosis. This review discusses some of those markers, particularly markers for which data are available that pertain to the progression to T1D. RECENT FINDINGS: A study of birth cohorts showed that young children who develop multiple autoantibodies are at a particularly high risk for developing T1D, and that there appears to be a typical sequence for autoantibody development. The measurement of autoantibodies by electrochemiluminescence can increase the prediction accuracy for T1D. A new marker of changes in glucose over 6 months (PS6 M) has potential utility as an endpoint in short-term prevention trials. Markers which combine C-peptide and glucose, such as the Diabetes Prevention Trial-Type 1 Risk Score and the Index60, can increase the accuracy of prediction, and can potentially be utilized as prediagnostic endpoints. β-cell death measurements could have substantial utility in future T1D research. SUMMARY: Markers are highly useful for studying the prediction of and progression to T1D. Moreover, markers can possibly be utilized to diagnose T1D at an earlier stage of disease.
Authors: Lars C Stene; Katherine Barriga; Michelle Hoffman; Jaime Kean; Georgeanna Klingensmith; Jill M Norris; Henry A Erlich; George S Eisenbarth; Marian Rewers Journal: Pediatr Diabetes Date: 2006-10 Impact factor: 4.866
Authors: Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren Journal: J Clin Invest Date: 1987-03 Impact factor: 14.808
Authors: Ping Xu; Craig A Beam; David Cuthbertson; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer Journal: Diabetes Care Date: 2012-07-11 Impact factor: 19.112
Authors: Jay M Sosenko; Jay S Skyler; Jerry P Palmer; Jeffrey P Krischer; David Cuthbertson; Liping Yu; Desmond A Schatz; Tihamer Orban; George Eisenbarth Journal: Diabetes Care Date: 2011-09-12 Impact factor: 19.112
Authors: Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer; Carla J Greenbaum; Jeffrey Mahon; Lisa E Rafkin; David Cuthbertson; Catherine Cowie; Kevan Herold; George Eisenbarth; Jerry P Palmer Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler Journal: Diabetes Care Date: 2009-12-23 Impact factor: 17.152
Authors: Paturi V Rao; Eric Bean; Dhanalakshmi Nair-Schaef; Siting Chen; Steven C Kazmierczak; Charles T Roberts; Srinivasa R Nagalla Journal: J Diabetes Sci Technol Date: 2021-03-17